ibSium's role in helping to reduce Irritable Bowel Syndrom (IBS) symptoms again recognized by the scientific community in a newly published peer-reviewed paper

摘要

Lesaffre Human Care has announced that ibSium~® has once more raised the interest of the scientific community. Indeed, the findings of a new clinical study have recently been accepted for publication in the renowned peer-reviewed 'United European Gastro-enterology Journal'. As reported in the article, ibSium~® demonstrated a significant effect in the improvement of gastrointestinal symptoms in subjects suffering from Irritable Bowel Syndrome with constipation (IBS-C). ibSium~® is a product containing a unique and patented strain of Saccharomyces cerevisiae, selected by Lesaffre among thousands of proprietary strains and registered with the French National Collection of Microorganism Cultures as CNCM Ⅰ-3856.